PROLEUKIN ACQUISITION - Cash consideration and allocated fair value of assets acquired and liability assumed (Details) - PROLEUKIN - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
May 18, 2023 |
Mar. 31, 2025 |
|
| Total cash consideration and allocated acquisition date fair values of assets acquired and liabilities assumed | ||
| Cash | $ 35 | |
| Inventory | 9,688 | |
| Deferred tax liability | (20,352) | |
| Total Cost of Acquisition | 222,672 | $ 222,700 |
| Developed technology | ||
| Total cash consideration and allocated acquisition date fair values of assets acquired and liabilities assumed | ||
| Intangible assets | 232,665 | |
| Assembled workforce | ||
| Total cash consideration and allocated acquisition date fair values of assets acquired and liabilities assumed | ||
| Intangible assets | $ 636 |